PRIDE-HD is a Phase II clinical research study of an investigational drug called pridopidine in people who have a diagnosis of Huntington disease (HD). Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington’s Disease Network (EHDN), with sponsorship by Teva Branded Pharmaceutical Products.
SD-809 ER (Auspex Pharmaceuticals)
SD-809 ER is an investigational study drug developed by Auspex Pharmaceuticals for the treatment of chorea. First-HD and ARC-HD are Phase III clinical trials that are currently enrolling. Both studies are evaluating SD-809 ER’s safety, tolerability and effectiveness in reducing chorea.
First-HD is designed for subjects who have not taken tetrabenazine in the past 6 months.
ARC-HD is for subjects who are currently taking tetrabenazine or those who participated in First-HD.
All participants are eligible for reimbursement of travel and lodging costs. Participants in ARC-HD may be eligible to receive at no cost the study drug and medical supervision for up to 12 months.
CREST-E: A global, multi-center, clinical trial run in collaboration with Massachusetts General Hospital investigating the effects of creatine monohydrate on the progression of Huntington disease, led by Dr. Steven Hersch.
PREDICT-HD 2.0 - Observational research study for at-risk gene positive, pre-symptomatic, and gene negative tested individuals, with headquarters at the University of Iowa, under the leadership of Dr. Jane Paulsen.
On-going HSG Research Studies & Clinical Trials (ENROLLMENT COMPLETED)
Reach2HD - A clinical research trial investigating the effects of PBT2 on invidividuals with early to mid-stage Huntington disease, led by Ray Dorsey of Johns Hopkins University and Diana Rosas of Massachusetts General Hospital.
2CARE: A multi-center, randomized, double-blind, placebo-controlled trial led by Merit Cudkowicz, Michael McDermott, and Karl Kieburtz, assesing the effects of coenzyme Q10 on inviduals with mild-to-moderate Huntington disease.
PREQUEL: A clinical trial investigating the safety and tolerability of coenzyme Q10 for individuals with pre-manifest Huntington disease, led by Dr. Christopher Ross (John Hopkins University) and co-led by Dr. Kevin Biglan (University of Rochester).